John Libbey Eurotext

European Journal of Dermatology

Microwave therapy for cutaneous human papilloma virus infection Volume 27, numéro 5, September-October 2017

  • [1] Cockayne S., Hewitt C., Hicks K. Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial. BMJ. 2011;342:d3271.
  • [2] Kwok C.S., Gibbs S., Bennett C., Holland R., Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;9:CD001781.
  • [3] Riddel C., Rashid R., Thomas V. Ungual and periungual human papillomavirus-associated squamous cell carcinoma: a review. J Am Acad Dermatol. 2011;64:1147-1153.
  • [4] Stern P.L. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol. 2005;32:S72-81.
  • [5] Soong R.S., Song L., Trieu J. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res. 2014;20:5456-5467.
  • [6] Edwards L., Ferenczy A., Eron L. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134:25-30.
  • [7] Bristow I., Walker N. Pulsed dye laser for the treatment of plantar warts - two case studies. Foot. 1997;7:229-230.
  • [8] Kimura U., Takeuchi K., Kinoshita A., Takamori K., Suga Y. Long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser treatment for refractory warts on hands and feet. J Dermatol. 2014;41:252-257.
  • [9] Park H., Choi W. Pulsed dye laser treatment for viral warts: a study of 120 patients. J Dermatol. 2008;35:491-498.
  • [10] Tosti A., Piraccini B.M. Warts of the nail unit: surgical and nonsurgical approaches. Dermatol Surg. 2001;27:235-239.
  • [11] Sterling J.C., Gibbs S., Haque Hussain S.S., Mohd Mustapa M.F., Handfield-Jones S.E. British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171:696-712.
  • [12] Kwok C.S., Holland R., Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011;165:233-246.
  • [13] Lloyd D.M., Lau K.N., Welsh F. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB (Oxford). 2011;13:579-585.
  • [14] Polak M.E., Thirdborough S.M., Ung C.Y. Distinct molecular signature of human skin Langerhans cells denotes critical differences in cutaneous dendritic cell immune regulation. J Invest Dermatol. 2014;134:695-703.
  • [15] Ressing M.E., de Jong J.H., Brandt R.M. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999;29:1292-1303.
  • [16] Bruggink S.C., Gussekloo J., Berger M.Y. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled trial. CMAJ. 2010;182:1624-1630.
  • [17] Emblation Medical Limited. Swift applicator instructions for use. Alloa, Scotland 2012.
  • [18] Karsai S., Daschlein G. Smoking guns”: Hazards generated by laser and electrocautery smoke. J Dtsch Dermatol Ges. 2012;10:633-636.
  • [19] Tan H.H., Goh C.L. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol. 2006;7:13-29.
  • [20] de Jong A., O’Neill T., Khan A.Y. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20:3456-3464.
  • [21] Bottcher J.P., Schanz O., Garbers C. IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function. Cell Rep. 2014;8:1318-1327.
  • [22] Schlitzer A., McGovern N., Teo P. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity. 2013;38:970-983.
  • [23] Vander Lugt B., Khan A.A., Hackney J.A. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol. 2013;15:161-167.
  • [24] Tussiwand R., Lee W.L., Murphy T.L. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature. 2012;490:502-507.
  • [25] Huber M., Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. Eur J Immunol. 2014;44:1886-1895.
  • [26] Raczkowski F., Ritter J., Heesch K. The transcription factor interferon regulatory factor 4 is required for the generation of protective effector CD8+ T cells. Proc Natl Acad Sci USA. 2013;110:15019-15024.
  • [27] Park J.S., Kim E.J., Kwon H.J., Hwang E.S., Namkoong S.E., Um S.J. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 2000;275:6764-6769.
  • [28] Muto V., Stellacci E., Lamberti A.G. Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes. J Virol. 2011;85:5070-5080.